Jeffrey Turner, MD
Associate Professor TermCards
About
Titles
Associate Professor Term
Co-Director Yale Hypertension Clinic, Nephrology; Nephrology Elective Director, Nephrology
Positions outside Yale
Medical Director Davita Branford, Nephrology, Yale School of Medicine
Biography
Dr. Turner is a clinical educator in the section of Nephrology. His responsibilities include patient care, teaching, and research.
The patients populations that Dr. Turner's clinical cares focuses on for are primarily those with kidney disease and hypertension. Dr. Turner has clinical expertise in a wide variety of kidney related ailments including nephrotic syndromes, glomerulonephritis, kidney disease in the setting of heart failure, diabetic nephropathy, and hypertensive associated kidney disease. Additionally, he is a certified specialist in hypertension and he cares for patients with resistant hypertension as well as those requiring specialized evaluations for identifiable secondary causes of hypertension.
In terms of teaching, Dr. Turner is a course director for the Yale School of Medicine Physician Associate Program and has a myriad of teaching responsibilities involving trainees at all levels (interns, residents, and fellows). He participates in a number of invited lectures at Yale New Haven Hospital as well as the Yale New Haven Health affiliated hospitals. Additionally, he has been an invited speaker at local at national meetings for various Nephrology associations.
Finally, Dr. Turner participates in clinical research at Yale as well. This includes serving as a site Principal Investigator for industry sponsored trials at the Yale Nephrology Office of Clinical Research as well as collaborating with colleagues in the Section of Cardiology at Yale on cardiorenal therapies in both animal and human models.
Appointments
Nephrology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Fellowship
- Montefiore Medical Center (2011)
- Chief Resident
- Montefiore Medical Center (2009)
- Residency
- Montefiore Medical Center (2008)
- MD
- New York Medical College (2005)
- BS
- San Diego State University, Biology (1999)
Research
Publications
2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightMore Is Better!!
Mehta P, Turner J. More Is Better!! Circulation Cardiovascular Quality And Outcomes 2024, 17: e011063. PMID: 38873760, DOI: 10.1161/circoutcomes.124.011063.Peer-Reviewed Original ResearchSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized controlled studyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease
Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Ochoa Chaar C. Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease. Annals Of Vascular Surgery 2024, 102: 25-34. PMID: 38307234, DOI: 10.1016/j.avsg.2023.11.044.Peer-Reviewed Original ResearchInsulin-requiring diabetes mellitusPeripheral arterial diseaseDiabetes mellitusInfrainguinal bypassInsulin requirementsArtery diseaseRisk of MALEBypass surgeryImpact of insulin useRates of primary patencyVascular Quality Initiative databaseOutcomes of patientsPeripheral arterial bypass surgeryInfrainguinal bypass surgeryStratification of patientsCrude rateElevated hemoglobin A1cArtery bypass surgeryAssociation of DMChronic limb-threatening ischemiaIncreased risk of MALEVascular Quality InitiativeLower extremity revascularizationAdverse limb eventsLimb-threatening ischemia
2023
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.Peer-Reviewed Original ResearchCurrent and Developing Technologies for BP Monitoring
Gunasekaran D, Turner J. Current and Developing Technologies for BP Monitoring. Current Cardiology Reports 2023, 25: 1151-1156. PMID: 37698819, DOI: 10.1007/s11886-023-01956-w.Peer-Reviewed Original ResearchIntravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CON
Turner J. Intravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CON. Kidney360 2023, 5: 648-650. PMID: 37287105, PMCID: PMC11146646, DOI: 10.34067/kid.0000000000000187.Peer-Reviewed Original ResearchDrug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsCarbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease
Lee S, Ali S, Cardella J, Turner J, Guzman R, Dardik A, Ochoa Chaar C. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. Journal Of Vascular Surgery 2023, 78: 201-208. PMID: 36948278, DOI: 10.1016/j.jvs.2023.03.029.Peer-Reviewed Original ResearchConceptsAdvanced chronic kidney diseaseChronic kidney diseasePeripheral vascular interventionsContrast volume usagePC-AKICarbon dioxide angiographyCardiac complicationsPropensity matchingKidney diseaseVascular interventionsPost-contrast acute kidney injuryAcute kidney injuryOutcomes of patientsPeripheral arterial diseasePoor renal functionMultivariate logistic regressionLower contrast volumeVolume of contrastCardiac comorbiditiesKidney injuryMinor amputationRenal complicationsRenal functionEndovascular therapyArterial diseaseIn-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mahoney D, Maulion C, Bellumkonda L, Turner J, Collins S, Wilson F, Krumholz H, Testani J. In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility. Circulation Heart Failure 2023, 16: e010206. PMID: 36896716, PMCID: PMC10186250, DOI: 10.1161/circheartfailure.122.010206.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureDiuretic responseDiuretic dosingOral diureticsHeart failureMulticenter cohortHospital observationLower readmission ratesNet fluid balanceDays postdischargeReadmission ratesHospital readmissionUrine outputReadmission riskFluid statusFluid balanceHospital measuresDose selectionCohortProvider decisionsWeight changeReadmissionDiureticsPatients
Clinical Trials
Current Trials
TARGET BP I Clinical Trial (TARGET BP I)
HIC ID2000025879RoleSub InvestigatorPrimary Completion Date03/31/2023Recruiting ParticipantsGenderBothAge18 years - 80 years
Academic Achievements & Community Involvement
Clinical Care
Overview
Jeffrey Turner, MD, is a nephrologist and co-director of the Yale Medicine Nephrology Hypertension Clinic. He treats all forms of kidney disease, both acute and chronic, as well as electrolyte abnormalities. He is certified by the American Society of Hypertension as a hypertension specialist, and he specializes in complex hypertensive syndromes.
"I'm in the business of improving people's quality of life,” Dr. Turner says. “That means different things to different people. Sometimes, it means recommending that they go on a medication; other times, it means just the opposite—not taking a medication but doing everything they can other than that to treat their disease." Either way, he encourages patients to be open about how they feel about a given treatment that may require a level of commitment on their part. “The more forthcoming someone is about what they're willing to do and not willing to do, the easier it is for me to work with them,” he says.
Mentors met in the course of his medical training inspired Dr. Turner to care for people with kidney disease and hypertension. He says they helped him develop his own approaches to caring for his patients and earning their trust. “It really all comes down to the mentors I’ve had—little tools from different people,” he says.
An associate professor at Yale School of Medicine, Dr. Turner has several research interests, including renal denervation for the treatment of hypertension, novel medical therapies for diabetic and non-diabetic chronic kidney disease, and new methods for addressing diuretic resistance in cardiorenal syndrome. He oversees the Nephrology Clinical Trials Office and manages a portfolio of nephrology-focused clinical trials for patients at Yale.
Clinical Specialties
Fact Sheets
Glomerulonephritis
Learn More on Yale MedicineAcute Kidney Injury (AKI)
Learn More on Yale MedicineHigh Blood Pressure (Hypertension)
Learn More on Yale MedicineChronic Kidney Disease
Learn More on Yale Medicine
Yale Medicine News
News
News
- February 15, 2024
Hybrid Approach to Arteriovenous Fistula Aneurysm Repair
- March 21, 2023
Department of Internal Medicine Promotions and Reappointments
- February 01, 2023Source: Yale Medicine
17 Things To Know About High Blood Pressure
- November 02, 2022
ASN Kidney Week 2022: Presentations from Yale Nephrology